Drug Delivery Business

Boston Scientific initiates coronary drug-coated balloon study in U.S.

By

Boston Scientific AGENT DCB
[Image from Boston Scientific]
Boston Scientific (NYSE:BSX) this week launched its Agent IDE trial for its Agent drug-coated balloon.

The U.S. prospective, randomized clinical trial will evaluate the safety and effectiveness of a drug-coated balloon (DCB) in patients with coronary in-stent restenosis in lesions up to 26 mm in length in a coronary artery 2.0 mm to 4.0 mm in diameter.

Get the full story at our sister site, Medical Tubing & Extrusion.

IN CASE YOU MISSED IT

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.